muramylnac-ala-isogln-lys-tripeptide and Crohn Disease

muramylnac-ala-isogln-lys-tripeptide has been researched along with Crohn Disease in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boneca, IG; de Jong, DJ; Dharancy, S; Ferwerda, G; Girardin, SE; Jéhanno, M; Mengin-Lecreulx, D; Netea, MG; Philpott, DJ; Sansonetti, PJ; Van Der Meer, JW; Werts, C	1
Ghosh, S; Hervé, M; Hunt, KA; Playford, RJ; van Heel, DA	1

Other Studies

2 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Crohn Disease

Article	Year
The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. The Journal of biological chemistry, 2005, Oct-28, Volume: 280, Issue:43 Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Cell Line; Crohn Disease; Down-Regulation; Frameshift Mutation; Genotype; Homozygote; Humans; Hydrolysis; Interleukin-10; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Models, Biological; Models, Chemical; Mutation; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptides; Peptidoglycan; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Teichoic Acids; Toll-Like Receptors; Transfection	2005
Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. European journal of immunology, 2006, Volume: 36, Issue:6 Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Genotype; Humans; Interleukin-1; Interleukin-8; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptidoglycan; Tumor Necrosis Factor-alpha	2006

Article

Year

The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists.

The Journal of biological chemistry, 2005, Oct-28, Volume: 280, Issue:43

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Cell Line; Crohn Disease; Down-Regulation; Frameshift Mutation; Genotype; Homozygote; Humans; Hydrolysis; Interleukin-10; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Models, Biological; Models, Chemical; Mutation; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptides; Peptidoglycan; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Teichoic Acids; Toll-Like Receptors; Transfection

2005

Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease.

European journal of immunology, 2006, Volume: 36, Issue:6

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adaptor Proteins, Signal Transducing; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Genotype; Humans; Interleukin-1; Interleukin-8; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Peptidoglycan; Tumor Necrosis Factor-alpha

2006